Heller SR, et al. - In this crossover study, researchers examined the safety of insulin degludec (degludec) in relation to age and risk of hypoglycemia post hoc in people with type 2 diabetes (T2D). Participants were randomly assigned to double-blind treatment with degludec or insulin glargine 100 units/mL (glargine U100) ± oral antidiabetic medications. Patients crossed over to the other treatment after 32 weeks. For people aged ≤ 65 and > 65 years, no significant differences in HbA1c reduction were evident. Overall, the investigators concluded that degludec was safe and effective in both younger and older people with T2D and hypoglycemia lower than glargine U100.